Evoke Pharma Inc (NAS:EVOK)
$ 4.3501 -0.0799 (-1.8%) Market Cap: 6.46 Mil Enterprise Value: 244,000.00 PE Ratio: 0 PB Ratio: 0.89 GF Score: 44/100

Q3 2022 Evoke Pharma Inc Earnings Call Transcript

Nov 09, 2022 / 09:30PM GMT
Release Date Price: $19.32
Operator

Good afternoon, and welcome to the Evoke Pharma's third-quarter 2022 earnings conference call. (Operator Instructions) Be advised that today's call is being recorded.

I will now turn the call over to Daniel Kontoh-Boateng. Thank you. You may begin.

Daniel Kontoh;Boateng
Tiberend Strategic Advisors, Inc. - VP

Good afternoon, and thank you for participating in Evoke Pharma's conference call today. With me today are David Gonyer, Evoke's Chief Executive Officer; Chris Quesenberry, Gimoti's Chief Commercial Officer from EVERSANA; and Matthew D'Onofrio, Evoke's Chief Business Officer.

By now, you should have a copy of the press release we issued earlier. If not, it is available on the Investor Relations page of our website at evokepharma.com. We encourage everyone to read today's press release as well as Evoke's quarterly report on Form 10-Q, which is now filed with the SEC. The company's 10-Q report and press release are also available on Evoke's website.

Please note that certain information discussed on the call today

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot